Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus

Vaccine

Volumn 27, Issue 44, 2009, Pages 6234-6238

  Biesova, Zuzana ^a   Miller, Mark A ^b   Schneerson, Rachel ^a   Shiloach, Joseph ^c   Green, Kim Y ^d   Robbins, John B ^a   Keith, Jerry M ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Hemagglutinin; Influenza; Rapid production

Indexed keywords

ALUMINUM POTASSIUM SULFATE; FORMALDEHYDE; HEMAGGLUTININ; INFLUENZA VACCINE; RECOMBINANT HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; ESCHERICHIA COLI; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, SYNTHETIC;

EID: 70349781658     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.107     Document Type: Article

References (34)

1. Collins S. Excess mortality from causes other than influenza and pneumonia during influenza epidemics (1932), United States Public Health Service, Washington, DC [11 November 1932]
2. Osterholm M.T. Preparing for the next pandemic. The New England Journal of Medicine 352 May 5 (18) (2005) 1839-1842
3. Wrigley N.G. Electron microscopy of influenza virus. British Medical Bulletin 35 January (1) (1979) 35-38
4. Waterfield M.D., Espelie K., Elder K., and Skehel J.J. Structure of the haemagglutinin of influenza virus. British Medical Bulletin 35 January (1) (1979) 57-63
5. Hobson D., Curry R.L., Beare A.S., and Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. The Journal of Hygiene 70 December (4) (1972) 767-777
6. Potter C.W., and Oxford J.S. Determinants of immunity to influenza infection in man. British Medical Bulletin 35 January (1) (1979) 69-75
7. Virelizier J.L. Host defenses against influenza virus: the role of anti-hemagglutinin antibody. Journal of Immunology 115 August (2) (1975) 434-439
8. Robbins J.B., Schneerson R., and Szu S.C. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. Journal of Infectious Disease 171 June (6) (1995) 1387-1398
9. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Disease 181 March (3) (2000) 1133-1137
10. Treanor J., and Wright P.F. Immune correlates of protection against influenza in the human challenge model. Developments in Biologicals 115 (2003) 97-104
11. Schild G.C., Oxford J.S., and Virelizier J.L. Immunity to influenza. Developments in Biological Standardization 28 (1975) 253-272
12. Meiklejohn G., Eickhoff T.C., and Graves P.I.J. Antigenic drift and efficacy of influenza virus vaccines, 1976-1977. Journal of Infectious Disease 138 November (5) (1978) 618-624
13. Barry R.D., and Mahy B.W. The influenza virus genome and its replication. British Medical Bulletin 35 January (1) (1979) 39-46
14. Wang R., Soll L., Dugan V., Runstadler J., Happ G., Slemons R.D., et al. Examining the hemagglutinin subtype diversity among wild duck-origin influenza A viruses using ethanol-fixed cloacal swabs and a novel RT-PCR method. Virology 375 May 25 (1) (2008) 182-189
15. Barnett D.J., Balicer R.D., Lucey D.R., Everly Jr. G.S., Omer S.B., Steinhoff M.C., et al. A systematic analytic approach to pandemic influenza preparedness planning. PLoS Medicine 2 December (12) (2005) e359
16. Johnson N.P., and Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bulletin of the History of Medicine 76 Spring (1) (2002) 105-115
17. Prabhu N., Prabakaran M., Ho H.T., Velumani S., Qiang J., Goutama M., et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. Journal of Virology 83 March (6) (2009) 2553-2562
18. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural & Molecular Biology 16 March (3) (2009) 265-273
19. Subbarao K., and Katz J.M. Influenza vaccines generated by reverse genetics. Current Topics in Microbiology and Immunology 283 (2004) 313-342
20. Hsiao J., Ahluwalia M., Kaufman J.B., Clem T.R., and Shiloach J. Adaptive control strategy for maintaining dissolved oxygen concentration in high density growth of recombinant E. coli. Annals of the New York Academy of Sciences 665 October (13) (1992) 320-333
21. Burnette W.N. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Analytical Biochemistry 112 April (2) (1981) 195-203
22. Taylor D.N., Trofa A.C., Sadoff J., Chu C., Bryla D., Shiloach J., et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infection and Immunity 61 September (9) (1993) 3678-3687
23. Nencioni L., Volpini G., Peppoloni S., Bugnoli M., De Magistris T., Marsili I., et al. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infection and Immunity 59 February (2) (1991) 625-630
24. FDA, CBER In: Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. U.S. Food and Drug Administration; 2007 www.fda.gov/cber/guidelines.htm.
25. Noah D.L., Hill H., Hines D., White E.L., and Wolff M.C. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clinical Vaccine Immunology 16 April (4) (2009) 558-566
26. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., and Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19 May 14 (25-26) (2001) 3444-3450
27. Shen S., Mahadevappa G., Oh H.L., Wee B.Y., Choi Y.W., Hwang L.A., et al. Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. Journal of Medical Virology 80 November (11) (2008) 1972-1983
28. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. Journal of Virology 82 July (13) (2008) 6200-6208
29. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 February 8 (13-14) (2001) 1732-1737
30. Schutze H. The optimal spacing of vaccine inoculation. Journal of Pathology of Bacteria 53 (1941) 443-451
31. Fecsik A.I., Butler W.T., and Coons A.H. Studies on antibody production. XI. Variation in the secondary response as a function of the length of the interval between two antigenic stimuli. The Journal of Experimental Medicine December 1 (120) (1964) 1041-1049
32. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19 September 15 (2-3) (2000) 213-216
33. Myers M.G., Beckman C.W., Vosdingh R.A., and Hankins W.A. Primary immunization with tetanus and diphtheria toxoids. Reaction rates and immunogenicity in older children and adults. JAMA 248 November 19 (19) (1982) 2478-2480
34. Zimmerman R.K. Adult vaccination. Part 1. Vaccines indicated by age. Teaching Immunization for Medical Education (TIME) Project. The Journal of Family Practice 49 September (9 Suppl.) (2000) S41-S50